Asian patients with de novo metastatic prostate cancer have better survival outcomes than White patients with the same condition, regardless of the type of treatment they received, according to a study published in the Journal of the National Comprehensive Cancer Network.
For this study, Dr. Xudong Ni and colleagues analyzed patient data from three large databases: the LATITUDE trial (764 patients), the SEER database (15,476 patients), and the National Cancer Database (10,366 patients). The study included 26,286 patients, of whom 2,781 were Asian and 23,505 were White.
From the LATITUDE trial, the researchers observed that the median overall survival (OS) rate was significantly longer in Asian patients than in White patients, whether they received androgen deprivation therapy (ADT) alone or combined with abiraterone. For patients treated with ADT, the median OS was 57.6 months in Asian patients and 32.7 months in White patients (HR, 0.51; 95% CI, 0.33-0.78; P =.002). However, for patients who received a combination of ADT and abiraterone, the median OS was not reached in Asian patients and was 43.8 months in White patients (hazard ratio [HR], 0.45; 95% CI, 0.28-0.73; P =.001).
Similarly, in the SEER database, Asian patients had a significantly longer median overall survival than White patients, with 53 months compared to 42 months (HR = 0.76, 95% CI 0.68-0.84, P < .001). Furthermore, Asian patients also showed a more improved cancer-specific survival (CSS). The median CSS was 52 months in Asian patients and 42 months in White patients (HR, 0.71; 95% CI, 0.63-0.80; P <.001).
Furthermore, in the National Cancer Database analysis, Asian patients again had longer median overall survival than White patients. In the overall cohort, the median OS was 38 months in Asian patients and 26 months in White patients (HR, 0.72; 95% CI, 0.62-0.83; P <.001).
“These data build on the mounting evidence of better survivorship outcomes for Asian patients with de novo metastatic PCa [prostate cancer] and will help to further refine the prognosis of Asian and White males with de novo metastatic PCa,” the researchers concluded. “Our data will also help improve planning for international trials in this disease space.”
Source: Renal & Urology News
Journal source: JNCCN
